Publicaciones en colaboración con investigadores/as de John Hunter Hospital (20)

2022

  1. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

    PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339

2021

  1. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

    Neurology, Vol. 96, Núm. 24, pp. E2989-E3002

2019

  1. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

    Multiple Sclerosis and Related Disorders, Vol. 28, pp. 235-243

  2. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

    npj Breast Cancer, Vol. 5, Núm. 1

2017

  1. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

    Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1346-1357

2016

  1. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

    Multiple Sclerosis, Vol. 22, Núm. 4, pp. 520-532

2015

  1. BREMSO: A simple score to predict early the natural course of multiple sclerosis

    European Journal of Neurology, Vol. 22, Núm. 6, pp. 981-989

  2. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

    Multiple Sclerosis, Vol. 21, Núm. 9, pp. 1159-1171

  3. Comparative efficacy of switching to natalizumab in active multiple sclerosis

    Annals of Clinical and Translational Neurology, Vol. 2, Núm. 4, pp. 373-387

  4. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS

    PLoS ONE, Vol. 10, Núm. 6

  5. Predictors of disability worsening in clinically isolated syndrome

    Annals of Clinical and Translational Neurology, Vol. 2, Núm. 5, pp. 479-491

2014

  1. Predictors and dynamics of postpartum relapses in women with multiple sclerosis

    Multiple Sclerosis Journal, Vol. 20, Núm. 6, pp. 739-746

  2. Risk of relapse phenotype recurrence in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 20, Núm. 11, pp. 1511-1522

  3. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent

    Annals of Neurology, Vol. 76, Núm. 6, pp. 880-890

2013

  1. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

    PLoS ONE, Vol. 8, Núm. 5

  2. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

    Brain, Vol. 136, Núm. 12, pp. 3609-3617

2012

  1. Country, sex, edss change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

    PLoS ONE, Vol. 7, Núm. 6

  2. Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis

    PLoS ONE, Vol. 7, Núm. 10

  3. Increasing age at disability milestones among MS patients in the MSBase Registry

    Journal of the Neurological Sciences, Vol. 318, Núm. 1-2, pp. 94-99

  4. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: Results from the MSBase Registry

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 83, Núm. 3, pp. 305-310